A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity.
R. D. Baird
No relevant relationships to disclose
B. Venugopal
No relevant relationships to disclose
R. S. Kristeleit
No relevant relationships to disclose
J. Charlton
No relevant relationships to disclose
M. Blanco-Codesido
No relevant relationships to disclose
E. Saunders
No relevant relationships to disclose
K. J. Shah
No relevant relationships to disclose
D. Crawford
No relevant relationships to disclose
P. Stephens
No relevant relationships to disclose
D. Wilkins
No relevant relationships to disclose
L. Sweeting
No relevant relationships to disclose
A. Forslund
Employment or Leadership Position - Johnson & Johnson
J. W. Smit
Employment or Leadership Position - Johnson & Johnson
P. A. Palmer
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
N. Fourneau
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
P. Hellemans
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
J. S. De Bono
Employment or Leadership Position - Institute of Cancer Research
Consultant or Advisory Role - Johnson & Johnson
Honoraria - Johnson & Johnson
R. Plummer
No relevant relationships to disclose
U. Banerji
Honoraria - Johnson & Johnson
Research Funding - Johnson & Johnson
T. R. J. Evans
Research Funding - Johnson & Johnson